News stories about Egalet (NASDAQ:EGLT) have trended somewhat positive on Tuesday, Accern reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Egalet earned a daily sentiment score of 0.19 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 46.4013433213712 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:
Shares of Egalet stock traded down $0.02 on Tuesday, hitting $0.62. The company had a trading volume of 145,329 shares, compared to its average volume of 928,948. The company has a market cap of $33.35, a PE ratio of -0.26 and a beta of 0.69. Egalet has a 1 year low of $0.55 and a 1 year high of $4.48. The company has a quick ratio of 2.30, a current ratio of 2.37 and a debt-to-equity ratio of -2.51.
Egalet (NASDAQ:EGLT) last issued its quarterly earnings data on Monday, March 12th. The specialty pharmaceutical company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.11. The company had revenue of $7.80 million during the quarter, compared to analysts’ expectations of $8.54 million. research analysts anticipate that Egalet will post -1.03 EPS for the current year.
Several analysts have recently commented on the company. Cantor Fitzgerald lowered their price objective on Egalet from $7.00 to $3.50 and set an “overweight” rating for the company in a research note on Tuesday, March 13th. Stifel Nicolaus downgraded Egalet from a “buy” rating to a “hold” rating and set a $1.50 price objective for the company. in a research note on Wednesday, January 3rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. Egalet has a consensus rating of “Hold” and an average price target of $5.50.
COPYRIGHT VIOLATION WARNING: This article was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.dispatchtribunal.com/2018/04/24/egalet-eglt-receives-daily-coverage-optimism-score-of-0-19.html.
Egalet Company Profile
Egalet Corporation, a specialty pharmaceutical company, develops, manufactures, and commercializes treatments for patients with pain and other conditions. It has licensed three approved pain products, such as SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; OXAYDO, an immediate-release oxycodone product designed to discourage abuse via snorting for the management of acute and chronic pain severe enough to require an opioid analgesic, and for which alternative treatments are inadequate; and ARYMO ER, an extended-release (ER) morphine product formulated with abuse-deterrent (AD) properties for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Receive News & Ratings for Egalet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Egalet and related companies with MarketBeat.com's FREE daily email newsletter.